Differential (Click to cross reference) activities of daily living advances in neurology adverse drug reaction Alzheimer's disease Alzheimer's disease, treatment of anticholinesterase antioxidant behavior cognition controversies in neurology cost effectiveness dementia dementia, treatment of donepezil efficacy evidence-based research facial hallucinations galantamine hallucination Lewy body disease, diffuse memantine metrifonate Mini Mental Status Examination nausea and vomiting nonsteroidal anti-inflammatory drug Parkinson disease Parkinson disease, dementia with practice guidelines premarin prosopometamorphopsia quality of life review article rivastigmine safety tetrahydroaminoacridine treatment of neurologic disorder weight loss

Showing articles 0 to 9 of 9 Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis JNNP 86:135-143, Wang, H.F.,et al, 2015 Prosopometamorphopsia and Facial Hallucinations Lancet 384:1998, Blom, J.D.,et al, 2014 Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005 Rivastigmine for Dementia Associated with Parkinson's Disease NEJM 351:2509-2518,2547, Emre,M.,et al, 2004 Drugs for Alzheimer's Disease BMJ 323:123-124, O'Brien,J.T . &Ballard,C.G., 2001 Rivastigmine (Exelon) for Alzheimer's Disease The Medical Letter 42:93-94, , 2000 Efficacy of Rivastigmine in Dementia with Lewy Bodies: a Randomised, Double-blind, Placebo-controlled International Study Lancet, 356:2031-2036,2024, McKeith,I.,et al, 2000 Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled BMJ 318:633-640, 615, Rosler,M.,et al, 1999 Pharmacologic Treatment of Cognition in Alzheimer's Dementia Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998 Showing articles 0 to 9 of 9